Dimensional Fund Advisors
NKTR icon

Dimensional Fund Advisors’s Nektar Therapeutics NKTR Stock Holding History

Dimensional Fund Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,380
Closed -$372K – 3320
2025
Q2 		$372K Sell
14,380
-10,530
-42% -$118K ﹤0.01% 3041
2025
Q1 		$255K Sell
24,910
-7,999
-24% -$105K ﹤0.01% 3099
2024
Q4 		$459K Sell
32,909
-706
-2% -$12.5K ﹤0.01% 3053
2024
Q3 		$654K Sell
33,615
-785
-2% -$15K ﹤0.01% 2985
2024
Q2 		$639K Sell
34,400
-1,851
-5% -$39K ﹤0.01% 2989
2024
Q1 		$508K Sell
36,251
-193
-0.5% -$2.02K ﹤0.01% 3039
2023
Q4 		$309K Sell
36,444
-2,755
-7% -$20.9K ﹤0.01% 3127
2023
Q3 		$350K Sell
39,199
-14,738
-27% -$142K ﹤0.01% 3112
2023
Q2 		$465K Sell
53,937
-85,027
-61% -$907K ﹤0.01% 3078
2023
Q1 		$1.46M Sell
138,964
-31,039
-18% -$939K ﹤0.01% 2816
2022
Q4 		$5.76K Buy
170,003
+86,512
+104% +$4.19M ﹤0.01% 2401
2022
Q3 		$4.01M Sell
83,491
-29,107
-26% -$1.73M ﹤0.01% 2496
2022
Q2 		$6.42M Sell
112,598
-20,909
-16% -$1.32M ﹤0.01% 2378
2022
Q1 		$10.8M Buy
133,507
+30,096
+29% +$4.45M ﹤0.01% 2262
2021
Q4 		$21M Buy
103,411
+19,077
+23% +$4.14M 0.01% 1959
2021
Q3 		$22.7M Sell
84,334
-22,975
-21% -$5.52M 0.01% 1934
2021
Q2 		$27.6M Buy
107,309
+43,847
+69% +$12.1M 0.01% 1896
2021
Q1 		$19M Buy
63,462
+11,197
+21% +$3.48M 0.01% 2056
2020
Q4 		$13.3M Sell
52,265
-451
-0.9% -$117K ﹤0.01% 2166
2020
Q3 		$13.1M Buy
52,716
+9,678
+22% +$3.04M 0.01% 2066
2020
Q2 		$14.9M Buy
43,038
+11,689
+37% +$3.65M 0.01% 2022
2020
Q1 		$8.39M Buy
31,349
+15,805
+102% +$4.89M ﹤0.01% 2192
2019
Q4 		$5.02M Buy
15,544
+5,731
+58% +$1.66M ﹤0.01% 2610
2019
Q3 		$2.68M Sell
9,813
-45,608
-82% -$16.7M ﹤0.01% 2784
2019
Q2 		$29.6M Buy
55,421
+12,249
+28% +$6.14M 0.01% 1824
2019
Q1 		$21.8M Buy
43,172
+15,937
+59% +$9.44M 0.01% 2003
2018
Q4 		$13.4M Buy
27,235
+12,270
+82% +$7.41M 0.01% 2201
2018
Q3 		$13.7M Buy
14,965
+613
+4% +$523K 0.01% 2304
2018
Q2 		$10.5M Buy
14,352
+484
+3% +$558K ﹤0.01% 2398
2018
Q1 		$22.1M Buy
13,868
+4,637
+50% +$5.97M 0.01% 2010
2017
Q4 		$8.27M Buy
+9,231
New +$5.46M ﹤0.01% 2445
2017
Q2 		– Sell
-1,021
Closed -$360K – 3321
2017
Q1 		$360K Hold
1,021
– – ﹤0.01% 3139
2016
Q4 		$188K Sell
1,021
-20,020
-95% -$4.07M ﹤0.01% 3210
2016
Q3 		$5.42M Sell
21,041
-9,122
-30% -$2.35M ﹤0.01% 2480
2016
Q2 		$6.44M Sell
30,163
-6,305
-17% -$1.41M ﹤0.01% 2408
2016
Q1 		$7.52M Sell
36,468
-27,640
-43% -$5.31M ﹤0.01% 2326
2015
Q4 		$16.2M Buy
64,108
+39,450
+160% +$8.11M 0.01% 1954
2015
Q3 		$4.05M Buy
+24,658
New +$4.36M ﹤0.01% 2591
2015
Q1 		– Sell
-90
Closed -$21K – 3377
2014
Q4 		$21K Hold
90
– – ﹤0.01% 3418
2014
Q3 		$16K Sell
90
-14
-13% -$2.68K ﹤0.01% 3455
2014
Q2 		$20K Hold
104
– – ﹤0.01% 3500
2014
Q1 		$19K Sell
104
-26
-20% -$5.15K ﹤0.01% 3511
2013
Q4 		$22K Sell
130
-27
-17% -$4.36K ﹤0.01% 3463
2013
Q3 		$25K Hold
157
– – ﹤0.01% 3485
2013
Q2 		$27K Buy
+157
New +$24.1K ﹤0.01% 3472

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors's NKTR Position: Q3 2025 in Review

Dimensional Fund Advisors sold out of Nektar Therapeutics (NKTR) in Q3 2025, closing a stake of 14,380 shares — an estimated $372K sold.

Dimensional Fund Advisors first reported a position in NKTR in Q2 2013 and held it in 45 quarters. The position peaked at $29.6M in Q2 2019. 154 funds tracked by Wall St. Rank hold NKTR as of Q3 2025.

  • Dimensional Fund Advisors reported no remaining Nektar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Dimensional Fund Advisors sold 14,380 Nektar Therapeutics shares in Q3 2025, an estimated $372K.
  • Dimensional Fund Advisors first reported a position in Nektar Therapeutics in Q2 2013 and held it in 45 quarters.
  • Dimensional Fund Advisors's Nektar Therapeutics position peaked at $29.6M in Q2 2019.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2025.

Based on Dimensional Fund Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.